Mary Wilson
Well-known member
09 November 2022
Smriti Mallapaty
Indonesia will be using the jab from next year, but some scientists say there is insufficient data to rule out that it could make infections worse in some people.
A vaccine to prevent infection from dengue — a mosquito-borne disease that kills 20,000 people a year — is poised to roll out in Indonesia next year. But the jab is stirring debate: some researchers say that important safety concerns have been overlooked.
The vaccine, called Qdenga and developed by the pharmaceutical company Takeda, headquartered in Tokyo, is particularly significant because it is the first for people who have not been exposed to dengue. The virus infects up to 400 million people a year. The Indonesian drug regulator approved use of the vaccine without testing for previous exposure in August. Europe’s drug regulator is also considering approving the vaccine without testing.
The only other approved vaccine, Dengvaxia, developed by Sanofi in Paris, can be given only to people who have already been infected. In individuals with no history of infection, Dengvaxia increases the risk of severe disease, including hemorrhagic fever, which might be caused by a rare but serious condition called antibody-dependent enhancement (ADE), in which vaccination induces antibodies that make a subsequent infection worse. ...
https://www.nature.com/articles/d41586-022-03546-2
Smriti Mallapaty
Indonesia will be using the jab from next year, but some scientists say there is insufficient data to rule out that it could make infections worse in some people.
A vaccine to prevent infection from dengue — a mosquito-borne disease that kills 20,000 people a year — is poised to roll out in Indonesia next year. But the jab is stirring debate: some researchers say that important safety concerns have been overlooked.
The vaccine, called Qdenga and developed by the pharmaceutical company Takeda, headquartered in Tokyo, is particularly significant because it is the first for people who have not been exposed to dengue. The virus infects up to 400 million people a year. The Indonesian drug regulator approved use of the vaccine without testing for previous exposure in August. Europe’s drug regulator is also considering approving the vaccine without testing.
The only other approved vaccine, Dengvaxia, developed by Sanofi in Paris, can be given only to people who have already been infected. In individuals with no history of infection, Dengvaxia increases the risk of severe disease, including hemorrhagic fever, which might be caused by a rare but serious condition called antibody-dependent enhancement (ADE), in which vaccination induces antibodies that make a subsequent infection worse. ...
https://www.nature.com/articles/d41586-022-03546-2